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Abbrevations 
AMI – Acute Myocardial Infarction 
CIVA – Central Intensive Care Unit 
CO – Cardiac Ouput 
COPD – Chronic Obstructive Lung Disease 
CT – Computed Tomography 
CVD – Cardiovasclar Disease 
DCI – Delayed Cerebral Ischemia 
EBI – Early Brain Injury 
ECG – Electrocardiography 
GCS – Glasgow Come Scale, 
HsTnT – High Sensitivity Troponin T, a biomarker indicating myocardial damage 
ICP – Intracranial Pressure 
IVH – Intraventricular Hemorrhage 
LP – Lumbar Puncture 
LVOTO – Left Ventricle Outflow Tract Obstruction 
MF – Modified Fischer, a grading scale for estimating magnitude of SAH 
NICU / ICU – Neurological Intensive Care Unit / Intensive Care Unit 
NIVA – Neuro Intensive Care Unit 
NT-proBNP – N-terminal Prohormon of Brain Natriuretic Peptide, a heart failure prohormone 
PiCCO - Pulse index Continuous Cardiac Output 
RLS – Reaction Grade Scale,  
RWMA – Regional Wall Motion Abnormalities 
SAH – Subarachnoid Hemorrhage 
SIC – Stress-Induced Cardiomyopathy 
WFNS – World Federation Neurosurgical Societies, a clinical grading scale of neurological symptoms  
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Abstract 
INTRODUCTION. Acute cardiac events are common after subarachnoid hemorrhage (SAH) 
and are associated with an increased risk of poor outcome. However, the impact of cardiac 
events on long term mortality after SAH is barely studied. 
OBJECTIVES. The aim was to evaluate the impact of acute cardiac events on long-term 
mortality after SAH. The hypothesis of this study was that these events are associated with an 
increased long-term mortality. 
METHODS. This is a retrospective study. Medical records from all patients admitted to our 
NICU and general ICU from 2010 to 2015 with the diagnosis SAH were analyzed. Variables 
obtained were age, medical history, WFNS score, modified fisher grade, cerebral infarction 
during hospital admission, treatment, troponin release and NTproBNP levels, ECG, 
echocardiograpic evaluation. Kaplan-Meier curves and Cox-regression were used in the 
statistical analyses. 
RESULTS. A total of 708 patients were admitted with suspected/verified SAH during the 
study period. 118 patients did not fulfill SAH-diagnosis, 33 patients were not included due to 
long time to admission (>4 days) and in 28 patients no ECG/echo/cardiac biomarkers were 
obtained. Of the 529 patients analysed, 109 patients had died at the time mortalily data was 
obtained (april 2016). In a univariate cox-regression model; WFNS grade 4-5, Fisher grade, 
age, history of hypertension, cardiovascular disease (CVD) or renal disease, levels of troponin 
and NTproBNP was significantly associated with a higher risk (hazard ratio) for death. A 
normal ECG was significantly associated with reduced mortality. Stress-Induced 
Cardiomyopathy was not significantly associated with an inreased risk of death. In a 
multivariable cox-regression model, both troponin levels and NTproBNP levels were 
significantly associated with an increased risk of death when adjusting for WNFS grade 4-5, 
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age, history of CVD or renal disease and Fisher grade. However, these differences were only 
significant the first year after the hemorrhage. 
CONCLUSIONS. Acute release of the cardiac biomarkers troponin and NTproBNP after 
SAH is an omnious clinical sign which is associated with an increased risk of death, 
especially the first year after the hemorrhage. Further research is needed to address whether 
measures to optimize cardiac treatment after SAH might improve outcome. 
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Introduction 
Patients with a Subarachnoid Hemorrhage (SAH) are often affected by cardiac complications 
in the acute phase of the hemorrhage.[1] These cardiac events differ greatly in clinical 
significance; from subclinical electrocardiography (ECG) changes, troponin release to acute 
heart failure[2, 3]. Several studies have shown that cardiac events are associated with worse 
short term prognosis, but only a few have explored the impact of long term outcome[4]. 
Stressed Induced Cardiomyopathy 
Overview 
Stress-Induced Cardiomyopathy (SIC) is a relatively new diagnosis with the first scientific 
reports emerging in the early 90s from Sato et al in Japan. It is often referred to as Tako 
Tsubo Cardiomyopathy for its resemblances of a Tako Tsubo octopus trap used by Japanese 
fishermen in Hiroshima fishing market[5]. The condition presents itself as hypokinesia in the 
left ventricle of the heart, where the heart muscle form a balloon-like shape with little or no 
movement in affected regions. The condition is also known as Apical Ballooning 
Cardiomyopathy, Transient Apical Ballooning Syndrome, Broken Heart Syndrome and 
Stressed Induced Cardiomyopathy[6], which it will be named in this report.  
Patients typically present with acute, angina-like chest pain, breathlessness and palpitations 
caused by arrhythmia or sinus tachycardia. In more severe cases the patient might experience 
pre-syncope or syncope due to ventricular tachyarrhythmia, cardiogenic chock or left 
ventricular outflow tract obstruction (LVOTO). Patients have described the chest pain as a 
wave of pressure emerging from the chest up to the neck and into the head. These symptoms 
are consistent with the catecholamine and hypertensive surge presented in SIC, frequently 
associated with anxiety and perspiration.[6] 
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The cause of the syndrome is still highly unknown but it has been shown to be strongly 
associated with catecholamine toxicity. The syndrome is usually preceded with a strong 
emotional or physical trigger prior to the debut, although there are reports that up to 33% of 
SIC-like diagnoses lack such a trigger prior the onset of symptoms[7]. Common emotional 
triggers are grief from losing a loved one, fear of public speaking, financial problems, arguing 
with a spouse or betrayal. Acute physical conditions such as asthma attacks, surgery, 
chemotherapy and stroke are examples of physical triggers. The symptoms of SIC mimic 
Acute Myocardial Infarctions (AMI) to a great extent and needs to be excluded when 
diagnosing a patient with SIC.[6] 
Epidemiology 
SIC is an uncommon condition. In a Nationwide Inpatient Study (NIS-USA) an estimated 
0.02% of all acute hospitalized patients were diagnosed with SIC. The majority of these 
patients where post-menopausal women (90%)[6], which is confirmed by several other 
studies (a second NIS-USA study estimated an 89% and a German registry study estimated a 
91% of patients being post-menopausal women)[8, 9]. The mean age of these patients where 
66.9 years of age and almost 60% of all patients were 65 years or older. Risk factors for SIC 
include excessive use of alcohol, smoking, hyperlipidemia and a variety of anxiety states. [9] 
Clinical Subtypes 
SIC is considered to be either primary or secondary. The primary variant is when the acute 
onset of cardiac symptoms is the main reason for a patient seeking medical care, usually at 
emergency medical facilities, primary care centers or acute cardiac facilities. These patients 
may or may not have an identifiably emotional trigger and may also have a variety of co-
morbidities, although none of these being responsible for the sudden surge of catecholamines. 
Secondary SIC carries a substantial portion of the total number of cases. These patients are 
already hospitalized for other conditions such as medical, surgical, psychiatric, anaestetic or 
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obstetric ones, and the sudden onset of catecholamine-oriented stress may be a complication 
of their primary condition or a specific treatment. In these cares, primary care should focus 
not only on SIC and its cardiac complications but also on the trigger. [6] 
Patients of old age have considerably higher risk of suffering from both SIC and related 
complications to the syndrome. Only 10% of patients are <50 years of age. At the age of ≥75, 
patients have a higher risk of in hospital complications and mortality (6.8% vs 2.8%).[6] 
Pathophysiology 
The pathophysiology of SIC is still highly unknown and findings to this date suggest that the 
mechanism behind the syndrome is complex, reflecting integrated and systemic physiological 
responses to severe, acute stress, which triggers cardiovascular responses to a sudden surge in 
endogenous or exogenously administrated catecholamines. These catecholamines seem to 
play a central role in the SIC pathology, as the identified trigger is most often unexpected and 
sudden stress, leading to a sympathetic activation being present at the onset of symptoms. 
Exogenous administration of catecholamines as part of medical treatment may yield similar 
responses leading to SIC, but triggering a secondary SIC.[6] There are two major 
physiological paradigms to consider here. The first being the hypothalic-pituitary-adrenal 
(HPA) axis and the cognitive centers of the brain, regulating the norepinephrine and 
epinephrine release as a response to a stress trigger. The second paradigm is the sympathetic 
activation and the response from the cardiovascular system, its coronary arteries, myocardium 
and peripheral blood vessels due to the sudden surge of catecholamines.[10, 11] 
Studies have shown that serum catecholamine levels at the initial stage of SIC is significantly 
higher than resting levels in the same patient. The serum level was also higher in these 
patients with SIC compared to patients with acute heart failure caused by acute myocardial 
infarction (AMI).[6] These findings suggest an excessive epinephrine release and HPA 
increase in SIC patients. There has also been reports of SIC after administration of 
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sympathomimetic drugs such as Dobutamine.[12] SIC has also been induced in animal 
models by administration of beta-agonists. The syndrome has also been observed in numerous 
hyperadrenergic conditions such as sepsis, pheochromocytoma, SAH and brain death.[13-16] 
There are several hypotheses surrounding the exact mechanisms behind SIC. The first ones 
proposed microvascular dysfunction, a dissolved coronary artery or coronary artery 
spasm[17]. Since the LV hypokinesia in SIC usually extended beyond the area of which one 
coronary artery can supply, either several coronary arteries have to be affected at the same 
time or an abnormal anatomy of the coronary arteries have to be present, making these 
hypotheses less likely. [18] 
In a recent conference of experts in the field, a summary of pathophysiological hypotheses 
was sub-divided into two groups; vascular and myocardial. Vascular hypothesis consisted of 
acute multivessel coronary spasm, aborted myocardial infarction with spontaneous 
recanalization and acute increased ventricular afterload. Myocardial causes were acute left 
ventricle out tract obstruction (LVOTO) and direct catecholamine-mediated myocardial 
stunning. There is no reason for these hypotheses to be mutually exclusive and studies have 
yielded conflicting results, indicating the pathophysiology of SIC might be a synergistic 
combinations of vascular and myocardial effects from the surge of catecholamines. [6] 
Catecholamine cardiotoxicity is well known and the first scientific reports on the matter 
originates from the 60’s[19]. 
Diagnosis 
There are several diagnostic criteria proposed in diagnosing SIC, including the Japanese 
Takotsubo Cardiomyopathy Group, The Mayo Clinic, the Takotsubo Italian Network and the 
Gothenburg Group. The Heart Failure Association set a series of 7 diagnostic criterias for SIC 
in 2015[6]: 
11 
 
1. Trasient regional wall motion abnormalities of LV or RV myocardium which are frequently, 
but not always, preceded by a stressful trigger (emotional or physical) 
2. The regional wall motion abnormalities usually extend beyong a single epicardial vascular 
distribution, and often result in circumferential dysfunction of the ventricular segments 
involved.  
3. The absence of culprit atherosclerotic coronary artery disease including acute plaque rupture, 
thrombus formation, and coronary dissection or other pathological conditions to explain the 
pattern of temporary LV dysfunction observed (e g hypertrophic cardiomyopathy, viral 
myocarditis.) 
4. New and reversible electrocardiography (ECG) abnormalities (ST-elevation, ST-depression, 
LBBB, T-wake inversion and/or QTc prolongation) during the acute phase (3 months) 
5. Significantly elevated serum natriuretic peptide (BNP or NT-proBNP) during the acute phase.  
6. Positive but relatively small elevation in cardiac troponin measured with a conventional assay 
(ie. disparity between the troponin level and the amount of dysfunctional myocardium 
present). 
7. Recovery of ventricular systolic function on cardiac imaging at follow-up (3-6 months) 
To differentiate SIC from AMI, guidance can be found in measuring elevated levels of hsTnT 
compared to time of symptom debut. It’s been demonstrated that in SIC, hsTnT is released 
shortly after onset of symptoms followed by a subsequent decline.[20] Whereas in myocardial 
infarction, peak levels are usually reached on day 2 or 3 after onset of symptoms. [21] The 
levels of hsTnT is however disproportionally low relative to the severeness of cardiac 
hypokinesia.[22] 
Treatment 
There are no randomized clinical trials that can support a specific recommendation of SIC-
management. A general goal is to reach recovery of normal heart function. Current 
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recommendations are based on treatment of congestive heart failure which have no scientific 
evidence for SIC. These treatments are suboptimal and could be potentially harmful[6, 23]. 
Risk stratification is essential for optimal treatment after diagnosing SIC. Risk factors are 
categorized into major risk factors (e.g age ≥ 75 years, Systolic BP < 110 mmHg, LVEF < 
35%, unexplained syncope, VT or VF) and minor risk factors (e.g age 70-75 years, LVEF 35-
45%, ECG with QTc ≥ 500 ms, pathological Q-waves, persistent ST-elevation). High risk is 
defined as the presence of at least one major or two minor risk factors and a clinical 
judgement is based on their severity.[6] A statement in European Journal of Heart Failure 
recommend that high risk patients should be monitored in a higher level hospital environment 
such as a coronary care unit or an intensive care unit. Lower risk cases of SIC where LVEF > 
45% and no other complications are presented may be in consideration for an early discharge 
from hospital care. If LVEF is in the range of 35-45% and the patient has no other presented 
complications, beta-blockers and other heart failure medication may be of consideration. 
Lower risk patients with SIC should be followed up within 3-6 months with a renewal of 
cardiac imaging to confirm recovery of RWMA as well as a review of the medication given as 
treatment for SIC.[6] 
SIC has a negative effect on LVEF and tachycardia is seen as a compensation mechanism to 
maintain CO. Thus, inotropes are a controversial treatment as pulse frequency is already 
raised and the myocardium might be even more stressed with exogenous administrated 
catecholamines, such as inotropes.  Cerebral perfusion pressure is important to maintain 
during SAH but can be challenging with a presence of acute heart failure in SIC. Cardiac 
output can be monitored with a PiCCO device.[20] 
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Complications 
Most cases of SIC have good prognosis with rapid recovery of LV function and the syndrome 
is generally seen as relatively benign. In hospital mortality range from 2 to 5% and death is 
mainly caused by refractory cardiogenic shock or ventricular fibrillation. [24-26] 
Most common complication is acute heart failure with an incidence of 12-45%. Mitral 
regurgitation, cardiogenic chock, arrhythmias, thrombus formation, pericardial effusion, 
ventricular wall rupture and right ventricular involvement are also known complications and 
need to be treated symptomatically. Thus, the importance of monitoring high risk patients is 
of utter importance.[6] 
Cardiac Dysfunction in SAH 
Cardiac dysfunction in the acute phase of SAH has been observed and known for a long 
period of time. The first publications were presented in 1903, a demonstration of increased 
blood pressure and arrhythmias after SAH[27]. It was first in the early 1990s that the first 
scientific descriptions of SIC were published. SIC was initially thought to be a separate 
condition from the cardiac events seen after SAH, and SAH was at first an exclusion criterion 
for the SIC-diagnosis.[28] As knowledge grew about this relatively unknown type of heart 
failure, SAH was accepted as a trigger.  
Subarachnoid Hemorrhage 
SAH is a cerebrovascular bleeding which in 80% of all cases is induced by an aneurysm 
rupture where blood flows into the subarachnoid space between the pia mater and the 
arachnoid membrane surrounding the brain. Non-aneurysmal bleedings include isolated 
prepontine SAH and generally have a good prognosis with low mortality. [29] 
Acute symptoms include a particular harsh headache, often described as “thunder-clap 
headache”, neck pain, photophobia and nausea. Most common neurological findings are 
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impaired consciousness ranging from mild downiness and confusion to coma. Focal 
neurological deficits may present themselves as cranial nerve dysfunction such as diplopia,  
include hemiplegia.[20] 
According to most studies, SAH carries an approximate of 51% mortality rate and on average 
one third of all patients need lifelong care after. The acute mortality is high, with 25% of all 
deaths occurring within the first 24 h and 10% before patients receives medical care. Most 
deaths occur within 2 weeks of onset of symptoms.[30] Poor neurological status on 
admission, age, magnitude of the hemorrhage are major factors correlating with poor 
outcome. Risk factors include hypertension,  smoking, use of cocaine and alcoholism are 
major identifiable risk factors for SAH.[31] 
SAH is rather rare type of cerebral hemorrhage and it accounts for approximately 5% of all 
strokes. However, the median age of onset is only 55 years of age with the high mortality rate, 
making the diagnosis account for as many loss-of life-years as patients with intracranial 
hemorrhage or ischemic stroke.[29] 
WFNS is used as a clinical scale to grade the initial clinical features of the SAH bleeding. 
Several other scales are used but this one is the most commonly and preferably used since it is 
based on the Glasgow Come Scale (GCS).[32] 
On hospital admission of a suspected SAH-patient, a computed tomography of the head is 
performed to confirm the diagnosis. If inconclusive, a lumbar puncture is performed after 6 
hours of the CT to detect traces of blood in cerebrospinal fluid. Once diagnosis is established, 
a CT angiography or cerebral angography is performed to locate the aneurysm. About 15% of 
all patients are expected to have multiple aneurysms, so careful evaluation of all cerebral 
vessels needs to be undertaken.[29] 
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SAH should always be suspected in patients with the typical presentation such as the sudden 
onset of severe headache, nausea, neck pain, vomiting, syncope and photophobia. Retinal 
hemorrhage, a diminished level of consciousness, meningismus and focal neurological 
deficits should be evaluated during physical examination. [29] 
Treatment 
Evaluating the patient on emergency basis is of utter importance when treating patients with a 
SAH. Airway and cardiovascular function need to be maintained. Once initially stable, patient 
should be transferred to centers dedicated to neurocritical care. The main goal of treatment is 
to minimize the risk and damage of rebleeding, vasospasm and treating other neurological and 
medical complications. Early treatment of aneurysms is the main treatment in preventing 
rebleeding. Oral calcium antagonists are administrated as they have been proved to reduce the 
risk of poor outcome associated with ischemic complications such as vasospasm.[33]  
The two main treatments for aneurysms consist of surgical clipping and endovascular coiling. 
Clinical trials suggest that early interventions yield better outcome than those who are treated 
later.[34] Securing a ruptured aneurysm have proven to be helpful in decreasing 
complications such as vasospasm.[35] 
Complications 
Brain damage is the major complication after a SAH and can be divided into early brain 
injury (EBI) and delayed cerebral ischemia (DCI).[36] The aneurysm ruptures in the onset of 
SAH, inducing an intracranial pressure (ICP) increase and as a response to this the Cushing 
reflex is activated, increasing blood pressure which further increases the ICP to the point 
where it is equivalent to the blood pressure. This happens within the first minute after the 
hemorrhage and ICP will then decrease unless intracranial hematoma or cerebrospinal fluid 
obstruction is present. During this process, cerebral perfusion level will drop resulting in a 
cerebral hypoperfusion which leads to an impaired level of consciousness. This hypoperfusion 
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leads to ischemic damages of the brain. A prolonged period of decreased cerebral perfusion is 
followed by poor neurological status on admission and worse prognosis of the patient. 
Intracerebral hemorrhage, cerebral inflammation and edema, impaired autoregulation, injury 
of the blood-brain-barrier and microcirculatory disturbances might further aggravate EBI. 
Hypoxia, re-bleeding and hydrocephalus are the most lethal complications in early EBI.[37] 
DCI is defined as cerebral ischemic events 48-72 h after the initial hemorrhage. Cerebral 
arterial vasospasm is a key component and is thought to be mediated by extravascular blood 
surrounding cerebral vessels. Microthrombi, microvascular constrictions, impaired auto-
regulation, endothelial injury and cortical spreading ischemia are also thought to be 
mechanisms of DCI. Feared complications at this stage of the hemorrhage is fever, 
inflammation, impaired hemodynamics and metabolic abnormalities.[20] 
Aim 
This study aims to evaluate the impact of acute cardiac events on long-term mortality after 
SAH, compared to patients who suffer from SAH without cardiac complications. Our 
hypothesis was that such events are associated with an increased long-term mortality. 
Material and method 
Study Definition and Methology 
This was a retrospective single center study. Medical records from Neurology Intensive Care 
Unit (NIVA) and Central Intensive Care Unit (CIVA) at Sahlgrenska University Hospital, 
Gothenburg, was collected on patients admitted between January 1st 2010 and December 31st 
2015 using the ICD-10 diagnose code for Subarachnoid Hemorrhage. The study is part of a 
series of studies about Stress-Induced Cardiomyopathy by Jonatan Oras, MD and PhD. The 
inclusion criterion was hospital admission for suspected SAH in the mentioned period of time. 
The exclusion criteria were traumatic SAH, planned surgical/endovascular intervention of e g 
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cerebral arteriovenous malformation with SAH-complication, absence of heart parameters 
such as ECG, Echocardiography, hsTnT, NTproBNP, benign/prepontine hemorrhage and a 
history of acute myocardial infarction (AMI). Between 2010 and 2012, NTproBNP and 
hsTnT was not part of routine lab tests in suspected SAH-patients, although the tests were 
done sporadically. 
For comparison of mortality between SAH-patients and the general population, an age and 
sex matched group were simulated using age/sex mortality data from the SCB for Västra 
Götalandsregionen, Matching 1 SAH patients to 10 non-SAH subjects. 
Patients with confirmed or suspected SAH were rapidly transported to NIVA or in some cases 
CIVA for intensive care. After hospital admission, a non-contrast computed tomography (CT) 
scan was made to confirm SAH-diagnosis. If radiology was inconclusive or not showing signs 
of SAH, a lumbar punction (LP) was performed 6 hours after the CT-scan. Only a few 
patients were confirmed to suffer from SAH using LP and most of these patients were 
diagnosed with a benign/prepontine hemorrhage and were excluded from the study. After 
confirmation of SAH-diagnosis, a cerebral angiography or a CT angiography was performed 
to locate the source of bleeding. Surgical or endovascular treatment were performed rapidly, 
usually within 24 h of admission. A calcium channel-antagonist, Nimodipine, was 
administrated to all suspected SAH-patients after CT and/or LP, as a prophylactic treatment of 
vasospasm and delayed cerebral ischemia (DCI). In this acute stage of SAH, many patients 
also had indication for and received treatment with hypertension, hypervolemia and iatrogenic 
agents. If SAH was confirmed and no source of bleeding was found, a new cerebral 
angiography or CT angiography was performed within 1 week for re-evaluation.  
In order to correctly confirm that the SAH study participants were accurately selected by the 
database search of ICD10-codes, each participant’s medical records where thoroughly 
reviewed. 
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Variables obtained for each SAH patient included in the study were: age, sex, time of 
admission, medical history, WFNS score, time to event (death or other factor making follow 
up not possible), endovascular/surgical intervention, modified fisher grade, troponin release, 
NTproBNP levels, ECG and echocardiographic evaluation.  
Variables explained 
ECG on hospital admission was evaluated and assessed for ST-elevation, negative T-waves, 
other ST-T abnormalities, long QT or u-wave, left bundle branch block (LBBB) or right 
bundle branch block (RBBB). If the first ECG was inconclusive or wrongly performed, the 
next ECG to date was used, usually performed a few minutes after the first one. 
Clinical grading of SAH was performed according to the World Federation of Neurosurgical 
Societies (WFNS) grading of SAH. This scale is based on the Glasgow Coma Scale (Table 1)  
Table 1. Description of WFNS-
score 
WFNS Description 
1 GCS 15 
2 GCS 13-14 
3 GCS 13-14 + motor 
deficits e.g. hemiplegia 
4 GCS 7-12 
5 GCS <6 
 
A neurological status was performed by a neurosurgeon, a neurologist or an anesthesiologist 
and a reaction level scale (RLS 85) was estimated. This corresponds to the motor component 
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of GCS. Verbal response and eye opening response was routinely evaluated and noted in the 
journal. WFNS score was dichotomized in the statistical analyses to WFNS 1-3 or WFNS 4-5. 
CT-grading of SAH was estimated using Modified Fischer scale (MF) on admission CT. The 
scale primary focuses on distribution and amount of blood leaked in the subarachnoid space 
(Table 2). The scale primary predicts the risk of cerebral vasospasm. 
Table 2 Description of Fisher grade 
Modified Fisher 
Grade Description 
1 No or minimal blood, no IVH 
2 Minimal/localized blood, with IVH 
3 Diffuse or focal thick blood, no IVH 
4 Diffuse or focal thick blood, with IVH 
 
Time to admission was estimated based on extracts from the patients’ medical records. Time 
of admission was always documented, and if time of onset of symptoms was unclear, an 
estimated time was used based on when the patient was last witnessed without symptoms. 
Due to the inaccuracy of this method, the time to admission was only used as an exclusion 
criterion. No analysis based on this data was performed. 
Medical history was obtained with focus on cardiac disease, cerebrovascular disease, 
hypertension, malignancy, renal disease, diabetes, COPD and other (e.g. rheumatoid arthritis). 
Neurosurgical intervention, if performed, consist of ventricular drainage, endovascular coiling 
and/or surgical clipping of subarachnoid aneurysms. Other interventions consisted of 
craniotomy, lumbar drainage, intracranial pressure monitoring and ventriculoperitoneal shunt.  
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Levels of NTproBNP and hsTnT was obtained if taken during hospital admission. The peak 
levels within three days of onset of symptoms was used in the analysis. Samples obtained 
later than 3 days of onset of symptoms were excluded from the analysis. 
Echocardiography was obtained if performed within 7 days of admission. Signs of 
hypokinesia or akinesia was documented by independent medical expertise, usually a 
cardiologist or a clinical physiologist. SIC was defined as transient RWMA without pre-
existing cardiac disease 
Outcome Variables and Predictors 
The primary outcome variable in this study was time to death, which was obtained from the 
hospital database connected to the Swedish Population Register. The primary predictors were 
the levels of cardiac biomarkers hsTnT and NTproBNP taken within three days of admission. 
The secondary predictors were SIC within a week of admission and ECG on admission. We 
adjusted for age, sex, WFNS score, modified fisher grade, medical history, treatment of 
aneurysm and cerebral infarction during hospital stay. 
Statistical Analysis 
All continuous variables were checked for normal distribution using histogram and Shapiro-
Wilks test. Normal distributed variables are presented as mean ± standard deviation, non-
normally distributed variables are presented as median (interquartile range). For comparison 
of means between two group with normally distributed variables, t-test was used. For 
comparison of medians between two groups with non-normally distributed variables, 
MannWhitney U test was used. For comparison of incidences between two groups with binary 
variables. Kaplan-Meier curves, uni- and multivariable Cox-regression hazard ratio were used 
in the survival analysis. In the multivariable analysis, variables with a p-value <0.10 in the 
univariable analysis were included in the multivariable analysis for adjusted analysis. In the 
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multivariable analysis, variables with a p-value <0.05 were considered significant. Software 
used was IBM SPSS ver 22.0. A p-value <0.05 was considered significant in the analyses. 
 
Data Collection Procedure 
Data collection was obtained through Melior, official platform for medical records used at 
Sahlgrenska University Hospital. Lab results was obtained through LabBest. Neurological 
imaging and independent evaluation by radiologists was obtained through WebAdapt.  
Ethics 
This study is approved by the local ethics committee in Gothenburg. Being a retrospective 
study of medical records, informed consent was not obtained. All patients where anonymized. 
Results 
Inclusion and patient characteristics 
A total of 708 patients were admitted with suspected/verified SAH during the study period. 
118 patients did not fulfill SAH-diagnosis, 33 patients were not included due to long time to 
admission (>4 days) and in 28 patients no ECG/echo/cardiac biomarkers were obtained. In the 
529 patients analysed, 109 patients had died at the time mortality data was obtained (april 
2016).  
Out of the 529 patients included in the study protocol, 439 patients (83%) were admitted on 
day 1, 55 patients (10%) were admitted on day 2 and 35 patients (7%) were admitted on day 3 
after onset of symptoms.  Our primary predictors, levels of hsTnT were obtained in 428 
patients (81%) and NTproBNP in 342 patients (65%). Secondary predictors; echo was 
performed on 237 patients (45%) and ECG in 457 patients (86%). Patients with WFNS 4-5 
were more commonly examined with echocardiography (60% of patients with WFNS 4-5 vs 
38% of patients with WFNS 1-3, p<0.001). This bias was not seen with the cardiac 
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biomarkers or ECG. A study flow chart of patient inclusion, exclusion and cadiac predictors 
obtained is shown in Figure 1.  
A total of 32 patients (13%) had an echocardiographic ultrasound confirming SIC.  
 
Fig. 1 A brief protocol of number of patient inclusion, exclusion and variables obtained. n = 
number of patients recieving the various tests. 
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Table 3.  Patient Characteristics 
 
 
Category Variable Value 
Admission data Age, years 58 (49-67) 
 
Female sex, N (%) 311 (59) 
Medical history Hypertension, N (%) 186 (35) 
 
Cardiac disease, N (%)   32 (6) 
 
Cerebrovascular disease, N (%)   24 (5) 
 
Previous SAH, N (%)     6 (1) 
 
COPD, N (%)   15 (3) 
 
Malignancy, N (%)   23 (4) 
 
Diabetes, N (%)   18 (3) 
 
Renal disease, N (%)   10 (2) 
Clinical SAH grade WFNS 1, N (%) 245 (46) 
 
WFNS 2, N (%) 109 (21) 
 
WFNS 3, N (%)   15 (3) 
 
WFNS 4, N (%)   90 (17) 
 
WFNS 5, N (%)   65 (12) 
Radiological SAH grade Modified Fisher 1, N (%)   78 (15) 
 
Modified Fisher 2, N (%)   94 (18) 
 
Modified Fisher 3, N (%) 130 (25) 
 
Modified Fisher 4, N (%) 223 (42) 
 
Intracerebral hemorrhage, N (%)   70 (13) 
Treatment Embolization, N (%) 284 (54) 
 
Surgery, N (%) 130 (25) 
 
Acute ventricular drainage, N (%) 210 (40) 
Cerebral infarction Cerebral infarction, N (%) 192 (36) 
Age parameter is presented as median (interquartile range) of all patients included. All values are presented as 
n (%)SAH; Subarachnoid hemorrhage, WFNS; World federation of neurosurgeon grading of SAH, COPD; 
Chronic obstructive pulmonary disease 
24 
 
Patient characteristics are presented in Table 3. Median age of patients in this study were 58 
years. A total of 311 patients (59%) were female, 186 patients (35%) had a history of 
hypertension and 32 patients (6%) had a history of cardiac disease. A total of 155 patients 
(29%) had WFNS grade 4-5, 233 patients (42%) had Modified Fisher grade 4 on admission 
CT and 192 patients (36%) had cerebral infarction between onset of SAH and hospital 
discharge or death. A total of 210 patients received treatment with acute ventricular drainage 
(40%), 284 patients (54%) received aneurysmal treatment by intravascular embolization and 
130 patients (25%) through open surgery by clipping. 
Cardiac variables 
Median level of hsTnT was 13ng/l and median level of NTproBNP was 785ng/l (Table 4). 
Levels of hsTnT was higher in patients with history of hypertension or cardiac disease, WFNS 
4-5, modified Fisher grade 4 or intracerebral hemorrhage. Levels of NTproBNP was higher in 
women, patients with history of hypertension, cardiac disease or cerebrovascular disease, 
patients with WFNS 4-5, modified Fisher grade 4 or intracerebral hemorrhage. SIC was more 
common in women (88% of SIC patients, p<0.001), patients with WFNS 4-5 (69% of SIC 
patients, p<0.001) while patients with history of hypertension had a lower incidence of SIC 
(16% of SIC patients, p=0.026). Patients with SIC had higher levels of hsTnT (median 17ng/l 
vs 437ng/l, p<0.001) and NTproBNP (median 1075ng/l vs 7245ng/l). Patients with SIC also 
had lower ejection fraction (median 51% vs 65%). An abnormal ECG was more common in 
patients with history of cardiac disease or cerebrovascular disease. WFNS or modified Fischer 
grade did not have an impact on having abnormal ECG. 
60% of all patients performing an echo had WFNS 4-5 on admission. Many patients with 
hsTnT-leakage and ECG-pathologies did not obtain an echo 
 
25 
 
 
 
 
 
hsTnT and NTproBNP are presented as median (interquartile range). The other variables are 
presented as n (%). SIC; Stress-induced cardiomyopathy 
 
Survival  
Overall mortality was 21% (109 of 529 patients) during the study period. A history of cardiac, 
cerebrovascular or renal disease was all associated with increased risk of death and was 
merged to one group, avoiding too small groups in the analysis. Patients with higher age, 
history of hypertension, cardiac-, cerebrovascular-, or renal disease had a higher risk of death. 
Furthermore, patients with admission status WFNS 4-5, intracerebral hemorrhage, modified 
Fisher grade 4 or cerebral infarction during hospital stay had a higher risk of death (Table 5). 
Table 4. Summary of 
cardiac variables in the 
population    
Category Variable Value 
Biomarkers Peak hsTnT, ng/l     13 (6-54) 
 Peak NTproBNP, ng/l            785 (368-1750) 
Echocardiography SIC, N (%)   32 (13) 
 Non-SIC, N(%) 205 (87) 
Electrocardiography Normal, N (%) 215 (47) 
 ST elevevations, N (%) 10 (2) 
 Negative T-wave , N (%) 20 (4) 
 Long QT/u-wave, N (%) 39 (9) 
 Other ST-T segment abnormalities, N (%) 124 (27) 
 RBBB/LBBB, N (%) 22 (5) 
 
Other (Q-wave, poor R-wave 
progression), N (%) 27 (6) 
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In a multivariable analysis, age, history of cardiovascular or renal disease, WFNS 4-5 and 
cerebral infarction were independently associated with a higher risk of death (Table 5).  
Of the cardiac variables, peak levels of hsTnT and NTproBNP were associated with an 
increased risk of death. Having a normal ECG was associated with a lower risk of death, this 
was the strongest variable associated with risk of death of the ECG variables. SIC was not 
significantly associated with an increased risk of death (Table 6). Ejection fraction was 
associated with an increased risk of death. Peak levels of hsTnT and NTproBNP were 
significantly associated with an increased risk of death also when adjusting for age, history of 
cardiovascular or renal disease, WFNS 4-5 and cerebral infarction. A normal ECG or ejection 
fraction was not significantly associated with lower risk of death when adjusting for these 
variables (Table 6). 
Kaplan Meier curves for WFNS 4-5, hsTnT and NTproBNP (divided by upper quartile or 
lower three quartiles), SIC and normal ECG are shown in Figure 2B-2E. Except for having an 
abnormal ECG, the differences in mortality observed in these groups were only significant the 
first year after the hemorrhage. Furthermore, comparing the whole SAH-population with 
age/sex matched controls; SAH-patients had the same mortality as controls one year after the 
hemorrhage (Figure 2A). 
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Fig 2. Kaplan Meier curves of survival. hsTnT (2C) and NTproBNP (2D) are divided by 
upper quartile or lower three quartiles. One year after the hemorrhage, mortality was the same 
in SAH-survivors as in the general population (A). WFNS 4-5 (B), hsTnT (C) and NTproBNP 
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(D) were also associated with an increased risk of death, but only the first year after the 
hemorrhage. Stress-induced cardiomyopathy was not associated with an increased risk of 
death (E). An abnormal ECG were associated with an increased risk of death, also later than 
one year after the hemorrhage.  
Table 5. Cox survival regression of medical history and admission variables, 
 Bivariable regression  Multivariable regression 
 HR  95% CI Sig  HR  95% CI Sig 
Age 1.06  1.04 - 1.07 <0.001  1.05  1.03 - 1.07 <0.001 
Female sex 1.35  0.93 - 1.97 0.114   -   -   -  
Hypertension 1.75  1.19 - 2.56 0.004  1.04  0.70 - 1.56 0.832 
Cardovascular disease or 
renal disease 
2.64  1.66 - 4.18 <0.001  1.70  1.06 - 2.74 0.029 
Previous SAH 1.74  0.43 - 7.05 0.438   -   -   -  
COPD 1.23  0.45 - 3.33 0.688   -   -   -  
Malignancy 1.81  0.88 - 3.72 0.107   -   -   -  
Diabetes 1.85  0.81 - 4.22 0.142   -   -   -  
Other 1.14  0.58 - 2.26 0.701   -   -   -  
WFNS 4-5 4.23  2.89 - 6.19 <0.001  3.26  2.13 - 4.98 <0.001 
Intracerebral hemorrhage 2.19  1.40 - 3.43 0.001  0.90  0.55 - 1.48 0.688 
Modified Fisher grade 4 2.36  1.61 - 3.47 <0.001  1.30  0.87 - 1.96 0.206 
Cerebral infarction 2.93  2.00 - 4.30 <0.001  1.87  1.24 - 2.83 0.003 
Embolisation vs surgery 0.81  0.56 - 1.18 0.268   -   -   -  
Non-cardiac Variables Cox Regression. HR; Hazard Ratio. 
Table 6. Cox survival regression of cardiac variables 
 Unadjusted  Adjusted 
 HR  95% CI Sig  HR  95% CI Sig 
Peak hsTnT, per 100ng/l 1.17  1.11 - 1.24 <0.001  1.08  1.02 - 1.15 0.014 
Peak NTproBNP, per 1000ng/l 1.09  1.06 - 1.11 <0.001  1.05  1.02 - 1.08 0.001 
Normal ECG 0.53  0.35 - 0.80 0.003  0.70  0.46 - 1.08 0.107 
Stress induced cardiomyopathy 1.68  0.87 - 3.24 0.124  1.26  0.63 - 2.52 0.507 
Ejection fraction 0.97  0.94 - 0.99 0.032  0.97  0.94 - 1.01 0.117 
In the adjusted analysis, cardiac variables were adjusted for age, history of cardiovascular or 
renal disease, WFNS 4-5 and cerebral infarction. HR; Hazard Ratio. 
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Discussion 
In this retrospective study, the aim was to evaluate whether acute cardiac events after SAH 
were associated with an increased long-term mortality. Cardiac biomarkers hsTnT and 
NTproBNP were both independently associated with increased risk of death while SIC and 
having abnormal ECG were not. However, these differences were only significant the first 
year after the hemorrhage. 
In this study, patients with a higher age, medical history of a cardiovascular or renal disease, 
poor neurological status on admission and cerebral infarction during hospital stay were 
independently associated with an increased risk of death. Both hsTnT and NTproBNP were 
associated with an increased risk of death also when adjusting for these non-cardiac variables 
strongly associated with an increased mortality. This suggests that myocardial damage, as 
measured with troponin release, has an additive role in the risk of dying after SAH (Figure 3). 
Since NTproBNP, a biomarker of cardiac dysfunction, and ejection fraction was associated 
with an increased risk of death; an impaired cardiac function might contribute to or be the 
mediator to a poor prognosis. However, the increased risk of death was only significant the 
first year after the hemorrhage so release of cardiac biomarkers did not affect long-term 
mortality. Our hypothesis was that cardiac events would increase the risk of death since it 
increases the risk of cerebral damage and a cardiac insult is associated with a higher risk of 
death in other patient groups. However, either our hypothesis was false or all patients with a 
cardiac event died in the acute phase of the disease. Surprisingly, SIC was not associated with 
an increased risk of death. This was unexpected since SIC is shown to be associated with 
increased mortality in other settings. Having an abnormal ECG on admission was associated 
with an increased risk of long-term mortality in the univariable analysis. However, some 
patients might have had an abnormal ECG due to diagnosed or undiagnosed chronic cardiac 
disease upon admission and ECG-abnormalities were not significant in the adjusted analysis. 
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Interestingly, we also found that SAH-survivors had the same mortality one year after the 
hemorrhage as the general population. 
Cardiac events after SAH are extensively studied. Several studies have shown an increased 
risk of poor functional outcome and an increased risk of short-term death [1, 38, 39]. 
However, the impact of cardiac events on long-term outcome is barely studied. To our 
knowledge, there are only two studies assessing the impact of cardiac events on long-term 
outcome. One of these studies, by Zaroff et al[4], was a register study and found that 
myonecrosis after SAH was associated with an increased long-term mortality and an 
increased risk of long-term cardiac events. However, this study did not adjust for other 
important variables of mortality such as WFNS score and age. The other study, by Bihorac et 
al [40], found that SIC was not associated with increased risk of mortality, as found in the 
present study.  
The overall long-term mortality of SAH patients are sparsely studied. One study by from 
Finland published in 2015 showed that SAH-patients carries a 17% increased mortality after 
20 years of ictus. [41] An American study published in 2009 estimated that standard mortality 
rate for SAH patients were 1.7 with a mean follow up time of 8.1 years.[42] Both these 
studies underline that long-term mortality data on SAH patients is scarce. 
To our surprise, we found in our study that the mortality was the same as in controls one year 
after the hemorrhage. Both studies referred to above have an inclusion from the 1980s. A 
review article [43] from 2013  suggested that the prognosis of SAH-patients is getting better. 
Our study is one of the first studies to validate the long-term mortality of SAH-patients is 
actually being improved over time. 
What is the possible relationship between myocardial damage and dysfunction and an 
increased risk of death? It is plausible that a decreased cardiac output contributes to a poor 
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perfusion pressure, especially since cerebral autoregulation is damaged after a SAH[44]. 
Endogenous catecholamines are also shown to increase cerebral oxygen demand in a damaged 
blood-brain barrier, which is found after SAH[45, 46]. This combination might be fatal in 
these patients. Another explanation might be that patients with troponin release suffer from a 
more serious brain injury in conjunction with the bleeding. When the aneurysm ruptures, 
blood enters the subarachnoid space and increases ICP rapidly, reaching a plateau at the same 
level as mean arterial pressure after approximately one minute after the bleeding[47, 48]. This 
increase in ICP leads to a decreased cerebral blood flow, ultimately leading to a cerebral 
hypoperfusion and the patient become unconscious[37, 49]. This might by physiological as it 
facilitates clotting of the ruptured aneurysm and ICP gradually normalizes within minutes in 
survivors[48]. However, the rapid rise in ICP and/or global cerebral ischemia initiates the 
Cushing reflex with an instant activation of the sympathetic nervous system and this 
activation might be more severe with more ischemia. Since we believe that sympathetic 
overstimulation is crucial for cardiac damage and SIC after SAH this might only reflect a 
more severe brain damage that could be used in addition to the clinical grading of SAH.  
Strengths and Weaknesses 
The main limitation of this study is that it is a retrospective single center study. However, all 
patients admitted with suspected SAH were consecutively included from the beginning of the 
study. The follow up time of patients and outcome was up to 6 years which may be 
considered as a weakness. However, the mortality was increased only the first year after 
hemorrhage in patients with biomarker release and compared to an age and sex-matched 
control group. The first 2 years of the study period, cardiac biomarkers were not taken on 
routine, making a possible bias for patients being more ill to receive these tests. 
Echocardiography was not performed on routine during any period of time during the study 
period, which may contribute a bias towards critically ill patients. This bias was supported by 
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our data, 60% of patients performing an echocardiography was either WFNS 4 or 5. In 
addition, many patients with hsTnT-leakage and ECG-pathologies did not obtain an 
echocardiography. One might argue that many sub-clinical SIC pathologies might have gone 
undetected through this study, as many patients had who had TnT leakage did not obtain an 
echo. A previous study has shown moderate hsTnT-increase in SAH patients with SIC, with a 
peak value on hospital admission in 90% of patients. [20] 
 
Conclusion and Clinical Implications 
Acute cardiac events after Subarachnoid Hemorrhage is common and may lead to impaired 
cardiac function. Studies show that such events have an increased mortality and that cardiac 
biomarkers hsTnT and NTproBNP identify high-risk patients that could benefit from intensive 
hemodynamic monitoring with hemodynamic optimization.  
We found that peak hsTnT and NTproBNP in the acute phase of subarachnoid hemorrhage is 
independently associated with an increased mortality up to 1 year after onset of symptoms. 
Further research is needed to address whether measures to optimize cardiac treatment after 
SAH might improve outcome. 
Stressed-induced Cardiomyopathy was not significantly associated with increased mortality in 
patients with SAH this study. However, the main test to indicate this condition being 
echocardiography is not taken on routine on these patients making a bias for more ill patients. 
Evaluating how SIC impacts on long-term mortality has proven to be challenging as previous 
studies are scarce and yield conflicting results.[4, 40] 
Populärvetenskaplig sammanfattning på svenska 
Subarachnoidalblödning är en fruktad form av hjärnblödning och karakteriseras av en plötslig 
kraftig huvudvärk ofta beskriven som en åskknall. En vanlig komplikation i samband med 
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detta är en påverkan på hjärtat som kallas för stressinducerad kardiomyopati, vilket innebär att 
delar av hjärtväggen rör sig mindre eller inte alls. Det är inte helt säkert hur detta sker men det 
finns starka kopplingar till ökad cirkulation av catecholaminer så som adrenalin i samband 
insjuknandet. I denna studie har man undersökt hur hjärtpåverkan i den akuta fasen av 
subarachnoidalblödning påverkar långtidsöverlevnaden genom att samla in data från 
journalsystem som används inom sjukvården. Genom att använda statistiska 
överlevnadsanalyser har man visat att hjärtmarkörerna hsTnT och NTproBNP är oberoende 
associerade till ökad risk för död upp till 1 år efter insjuknande. Man kunde inte se att 
stressinducerad kardiomyopati var associerat med ökad risk för död. Dock så görs ej testet för 
att påvisa denna hjärtpåverkan rutinmässigt vid insjuknande av en subarachnoidalblödning 
och det finns risk att många patienter som hade en hjärtpåverkan likt denna inte noterades. 
Det är viktigt att framtida forskning inriktar sig på att utvärdera betydelsen av hsTnT och 
NTproBNP i samband med subarachnoidalblödning för att optimera hjärtbehandling i 
samband med detta insjuknande. 
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